Abstract |
Darunavir (Prezista®), administered in combination with ritonavir and background antiretroviral therapy, is approved in the USA and the EU for the treatment of HIV-1 infection in pediatric patients aged ≥3 years. Ritonavir-boosted darunavir provided effective virologic suppression in treatment-naïve adolescents with HIV-1 infection, according to the results of the noncomparative, phase II DIONE trial. Ritonavir-boosted darunavir also had sustained efficacy in treatment-experienced children and/or adolescents with HIV-1 infection, according to the results of the noncomparative, phase II DELPHI and ARIEL trials. Ritonavir-boosted darunavir was generally well tolerated in pediatric patients with HIV-1 infection. Although more data are needed in pediatric populations (particularly data comparing darunavir with other antiretroviral agents), ritonavir-boosted darunavir is an important option for the treatment of pediatric patients with HIV-1 infection.
|
Authors | Gillian M Keating |
Journal | Paediatric drugs
(Paediatr Drugs)
Vol. 17
Issue 5
Pg. 411-21
(Oct 2015)
ISSN: 1179-2019 [Electronic] Switzerland |
PMID | 26323490
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Retroviral Agents
- HIV Protease Inhibitors
- Darunavir
|
Topics |
- Anti-Retroviral Agents
(therapeutic use)
- Child
- Darunavir
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- HIV Infections
(drug therapy)
- HIV Protease Inhibitors
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- HIV-1
- Humans
|